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ackground: Methicillin resistance in Staphylococcus aureus (MRSA) is creating crises in therapeutic 
options for the treatment of S. aureus associated infections, worldwide. Nevertheless, Zinc oxide 
nanoparticles (ZnO-NPs) are providing a source of an attractive broad-spectrum antibiotic. The aim of the 
present study was to investigate the synergistic effects of ZnO-NPs and antibiotics against mecA positive MRSA 
isolates.  
Methods: Antibiogram of S. aureus was determined by Kirby Baur disc diffusion assay. The minimum inhibitory 
concentration (MIC) of antibiotics and ZnO-NPs was determined by using the broth dilution method. The mecA 
gene in S. aureus was detected by PCR amplification with gene specific forward and reverse primers. The effects 
of subinhibitory concentration of ZnO-NPs on conventional antibiotics was determined by combined disk 
diffusion assay. 
Results: Out of two hundred clinical specimens, twenty-eight showed the growth of S. aureus. Antibiogram of 
the isolates showed that S. aureus have acquired resistance to the majority of the conventional antibiotics. 
However, no isolate showed resistance to vancomycin. The confirmed methicillin resistant S. aureus isolates 
were sensitive to ZnO-NPs. The antibacterial activity of ZnO-NPs appeared in a dose and time dependent 
manner since higher dose produced stronger effects in two hours than the effects produced from lower dose in 
three hours. Furthermore, ZnO-NPs enhanced the antibacterial activity of levofloxacin significantly (p < 0.001). 
Conclusions: S. aureus has acquired strong resistance to multiple antibiotics. ZnO-NPs have potential synergism 
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Staphylococcus aureus are Gram-positive bacteria that 
cause a variety of infections including skin and soft 
tissue, burn and wound infections in both community and 
hospital settings [1]. S. aureus becomes resistant to β- 
lactam antibiotics including methicillin and/or oxacillin 
due to the independent acquisition of staphylococcal 
cassette chromosome mec (SCCmec) [2]. 
Consequently, the infections caused by S. aureus have 
become a challenge to public health worldwide. 
However, a marked geographical variation in the burden 
of MRSA has been found which is  attributed to the 
diversity of local clones of MRSA strains and the locality 
wise differences in infection control programmes and 
practices [3].  
Due to clonal diversity among MRSA and their 
specificity in the acquisition of SCCmec, it is essential 
that the antibacterial activity of conventional antibiotics in 
combination with alternative therapeutic options should 
be investigated using the local clones of MRSA. One of 
these options is to use ZnO-NPs for the treatment of 
MRSA associated infections. ZnO-NPs have reportedly 
shown activity against a wide range of bacteria [4]. The 
antimicrobial activity of ZnO-NPs is associated with a 
novel toxicity mechanism. Electron-spin resonance 
measurements have revealed that an aqueous 
suspension of ZnO-NPs produces amplified levels of 
reactive oxygen species, namely hydroxyl radicals [5]. 
Recently, a complex mechanism of antimicrobial action 
that involves multiple metabolic pathways has been 
suggested for the anti MRSA activity of ZnO-NPs [6]. 
ZnO-NPs possess a number of dermatological 
properties and are among the highly desirable anti 
MRSA agents [7]. In fact, ZnO-NPs are under 
consideration for the treatment of MRSA associated 
infections. The specificity to the host cell, the lowest 
activity against human cells while having selective 
toxicity against target cells make them an ideal source of 
anti MRSA agent.  
Taken together, the clonal diversity among MRSA, the 
challenge imposed by multidrug resistant MRSA strains 
and the anti MRSA potential of ZnO-NPs,  the present 
study was designed to characterize local MRSA clones 
and to evaluate the effects of ZnO-NPs on the 
antibacterial properties of conventional antibiotics 
including levofloxacin. Levofloxacin is a fluroquinolone 
that can be used as an alternative option to treat MRSA 
associated infection. However, levofloxacin resistance in 
MRSA brings a catastrophe to public health [8]. 
Therefore,  the potential of synergism of ZnO-NPs with 
levofloxacin antibiotic may open doors for the future 
research to investigate synergy and the mechanism of 
synergism between these two antibacterial agents and 
the development of the strategies of future combinational 
therapy against a top priority pathogen, MRSA. 
Methods 
This is a cross sectional study conducted during a period 
of two years. The present study was approved from 
advanced studies and research board, Quaid-i-Azam 
University, Islamabad. 
 
Bacterial strains, media, and growth conditions 
All the media used in the present study, Muller Hinton 
agar medium (MHA), Nutrient agar (NA) and Nutrient 
broth (NB), and Mannitol salt agar (MSA), were 
purchased from Oxoid, UK. Bacterial cultures were 
grown aerobically at 35 ± 1ºC for 24 hours. ZnO-NPs was 
purchased from Sigma, Aldrich. 
Isolation and the preliminary identification of S. 
aureus isolates 
In the present study, 28 S. aureus strains were isolated 
from clinical samples such as pus swabs, throat swab, 
ETT tips (n=200) collected from a diagnostic laboratory 
connected with a tertiary care hospital of Rawalpindi, 
Pakistan. The isolation of S. aureus was based on their 
colony morphology on MSA medium. Identification was 
done using Gram-staining and standard biochemical 
tests such as mannitol fermentation, hemolysis, and 
catalase, coagulase, urease, DNase production tests.  
Antibiotic sensitivity patterns of S. aureus 
The antibiotic susceptibility of the clinical isolates of S. 
aureus (n=28) was determined using Kirby Baur disk 
diffusion assay according to CLSI guidelines and Zone 
of inhibition around an antibiotic disc was measured and 
compared with “Disc diffusion supplement table” [9]. The 
commercially available antibiotic discs used in the 
present study and their concentrations are listed in table 
1.  
Detection of mecA gene 
The template DNA of the all S. aureus strains (identified 
as MRSA based on antibiotic susceptibility assay) was 
obtained by using Wizard Genomic DNA extraction kit 
(Promega Inc., Madison, WI, USA). The procedure for 
DNA extraction was performed according to the 
recommendations of manufacturer. The quantity and 
quality of the extracted DNA was assessed using the 
Nanodrop-2000 spectrophotometer and agarose gel 
electrophoresis, respectively. PCR was performed using 
MRSA template DNA and a pair of primers reported 
previously [10]. The primers were mecA_1 (AAA-ATC-
GAT-GGT-AAA-GGT-TGG-C) and mecA_2 (AGT-TCT-
GCA-GTA-CCG-GAT-TTG-C), used to amplify 533bp 
fragment corresponding to the mecA gene. A well 
characterized MRSA strain from our laboratory was used 
as a control strain [11]. 
Determination of the minimum inhibitory 
concentration (MIC) of antibiotics 
The MIC of ampicillin, cefotaxime and levofloxacin was 
determined by an agar dilution method using the two-fold 
dilutions of antibiotics. The final concentration of the 
levofloxacin, cefotaxime and ampicillin in different plates 
was 512, 256, 128, 64, 32, 16, 8, 4, 2, 1 and 0 µg/ml.  
Determination of the anti MRSA activity of ZnO-NPs  
The antibacterial activity of ZnO-NPs was assessed 
against the MRSA isolates (mecA positive) of the present 
study (n=13) by a broth dilution method using NB 
medium. Two concentrations of ZnO-NPs (100µg/µl and 
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200µg/µl) were prepared and sterilized. Sonication was 
done to prepare uniform colloidal suspension. A single 
colony of test MRSA strains was grown overnight with 
shaking (200 rpm) at 35 ± 1ºC. The overnight cultures 
were diluted to achieve 1.5  ͯ 108 cfu/ml cells. Then, the 
MRSA cultures were grown in liquid medium in a total 
volume of 5 ml supplemented with ZnO-NPs colloidal 
suspensions with respective final concentration of 
10µg/ml (low dose), and 20µg/ml (high dose). The 
culture without the treatment of ZnO-NPs served as a 
control. The culture turbidity was used as a qualitative 
measure of cell growth. The experiments were 
performed in triplicate and repeated at least twice. 
Effects of ZnO-NPs on the activity of antibiotics 
To determine the combined effects, each standard 
antibiotic paper disk was further impregnated with 20µl 
of ZnO-NPs (final concentration of 500-2000 µg per 
disk). The sensitivity of MRSA isolates against the 
combined disks (an ineffective concentration of a 
conventional antibiotic and a subinhibitory concentration 
of ZnO-NPs) was determined by disc diffusion assay and 
a checkerboard was established. 
Results  
Antibiogram of S. aureus isolates 
A total of 28 S. aureus isolates were recovered from the 
clinical samples (n=200). The antibiogram of S. aureus 
isolates showed that they have acquired resistance to 
oxacillin/methicillin and can primarily be considered as 
MRSA isolates. Antibiotics from other major classes 
such as cephalosporins and quinolones were also 
ineffective to S. aureus isolates (Table 1). All S. aureus 
isolates of the present study were resistant to 
levofloxacin (100%) while linezolid was effective against 
92.86 % (n=26) S. aureus isolates.  Fortunately, no 
vancomycin resistant S. aureus was found in the present 
study suggesting that vancomycin remains an effective 
antibiotic against MRSA and can be used as a last resort 
therapy for the treatment of MRSA associated infections.  
Antibiotics 
(Concentration, µg) 
S. aureus (n=28) 
Sensitive Intermediate Resistant 
(n=) % (n=) % (n=) % 
Amoxicillin (10) 0 0 0 0 28 100 




0 0 0 0 28 100 
Cefoxitin (30) 0 0 0 0 28 100 
Ceftazidime (30) 0 0 0 0 28 100 
Cefuroxime (30) 0 0 0 0 28 100 
Ceftriaxone (30) 0 0 0 0 28 100 
Cefixime (5) 0 0 0 0 28 100 
Erythromycin (15) 04 14.29 0 0 24 85.71 
Gentamycin (10) 04 14.29 04 14.29 20 71.42 
Levofloxacin (5) 0 0 0 0 28 100 
Linezolid (1) 26 92.86 02 7.14 0 0 
Methicillin (5) 0 0 0 0 28 100 
Oxacillin (5) 0 0 0 0 28 100 
Vancomycin (30) 28 100 0 0 0 0 
Table 1: Antibiogram of S. aureus isolates of the present study. 
Molecular characterization of MRSA 
Of the 28 S. aureus isolates, 13 (46.43%) were mecA 
positive (Figure 1). Data showed that the rate of 
acquisition of multiple drug resistance was higher in the 
confirmed MRSA isolates.  The MIC of ampicillin, 
cefotaxime, and levofloxacin was much higher for the 
MRSA isolates (Table 2). The higher MIC values 
highlight the presence of strong antibiotic resistance in 
the mecA positive MRSA isolates. 
 
Figure 1: Agarose gel electrophoresis analysis of PCR production 
(533bp) corresponding to the mecA gene Lane M: marker 
(100bp), lane 1 mecA positive control, lane 2-8: seven MRSA 
isolates showing the mecA positive genotype. 
S. aureus 
isolates 
Minimum Inhibitory concentration of antibiotics 
(µg/ml) 
Amoxicillin Cefotaxime Levofloxacin 
CLSI 
breakpoints 
S R S R S R 
≤ 4 ≥ 8 ≤1 ≥4 ≤0.12 ≥2 
Ms_1 128  256  128  
Ms_2 256  >512  16  
Ms_3 32  01 04  
Ms_4 32  256  64  
Ms_5 128  >512  08  
Ms_6 64  >512  32  
Ms_7 512  512  32  
Ms_8 32  512  16  
Ms_9 64  32  32  
Ms_10 128  16  16  
Ms_11 64  >512  >512  
Ms_12 256  32  32  
Ms_13 256  >512  >512  
Tables 2: The MIC of ampicillin, cefotaxime, and levofloxacin for 
the mecA positive MRSA isolates (n=13). 
Anti MRSA activity of ZnO-NPs 
Furthermore, the antibacterial effects of ZnO-NPs 
against MRSA were observed in dose dependent 
manner. The effects of low dose of ZnO-NPs (0.10 µg/ul) 
on the growth of  mecA positive MRSA were observed 
after 3hrs of ZnO-NPs treatment and high dose of ZnO-
NPs (0.20 µg/ul) showed killing of the MRSA cells at 2hrs 
post treatment in the liquid culture (Figure 2). However, 
the curve gradually returned to increase, and culture 
started to become turbid after 5 hrs, suggesting that 
these concentrations can decrease the load of MRSA, 
but the MIC would be much higher than these doses. The 
MIC experiments showed that the concentration 
between 500-1000µg/ml was required to inhibit the 
growth of the majority of mecA positive MRSA isolates 
while disk diffusion assay showed that >2000 µg/disk 
ZnO-NPs was effective against mecA positive MRSA 
isolates. 
Effects of ZnO-NPs in combination with 
conventional antibiotics against MRSA 
The combined effects of ZnO-NPs and the conventional 
antibiotics were determined by using combined disc 
diffusion assay. It was observed that the subinhibitory 
concentration of  ZnO-NPs enhanced the antibacterial 
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activity of amoxicillin/clavulanic acid (30/10µg) and 
levofloxacin (5µg) against 69.23 (n=09) and 76.92 (n=10) 
MRSA isolates, respectively (Table 3). However, no 
effect of ZnO-NPs was found on the activity of ampicillin 
(25µg), cefoxitin (30µg) and oxacillin (1µg). The data 
showed that the 2000µg of ZnO-NPs was able to 
increase the efficacy of levofloxacin antibiotic 
significantly (p < 0.001) (Table 4). The synergy between 
ZnO-NPs (2000 µg) and levofloxacin (5 µg) was found in 
76.92% (n=10) confirmed MRSA isolates. Our results 
suggest that the ZnO-NPs with levofloxacin is synergistic 
with respect to multidrug MRSA killing. 
 
Figure 2: Anti MRSA effects of ZnO-NPs determined by optical 
density (OD600) for at least 4 hrs of post treatment with ZnO-NPs. 
High dose ZnO-NPs, 20µg/ml (□), Low dose ZnO-NPs, 10µg/ml 









Ms_1 - - 
Ms_2 + + 
Ms_3 + - 
Ms_4 + + 
Ms_5 + + 
Ms_6 + + 
Ms_7 - - 
Ms_8 + + 
Ms_9 + + 
Ms_10 + + 
Ms_11 + + 
Ms_12 + + 
Ms_13 - - 
Table 3: The combined effects of ZnO-NPs and antibiotics 
Concentrations of 
ZnO-NPs (µg) 




500 0 0 (0 0 
1000 0 5.10 ± 1.64 0 
2000 0 7.70 ± 1.61 0 
Table 4: Average size of zones of inhibition observed from the 
combined effects of subinhibitory concentration of ZnO-NPs and 
Levofloxacin. 
Discussion  
One of the dangerous phenomena of the current age is 
the increasing antibiotic resistance which is multiplied 
and intensified by the lack of the introduction of new 
antibiotics in the armory [12]. Currently, the first line 
therapy has almost failed to provide the treatment of 
bacterial infections. One example is of ineffectiveness of 
methicillin/ oxacillin in the treatment of S. aureus 
associated infections due to the high frequency of the 
prevalence of MRSA worldwide [13, 14]. Therefore, 
researchers are focusing on the identification and 
development of alternative therapeutic approaches. In 
this wave, ZnO-NPs have been reported to possess 
exceptionally beneficial safety profile and no toxicity 
detected when taken at different nano sizes alone [15]. 
Moreover, this compound is an extremely safe 
compound and may be taken into consideration for 
combinational therapy against S. aureus, due to its 
possible synergistic effect with important antibiotics. In 
view of these facts, the present study was conducted to 
explore the effects of ZnO-NPs on the efficiency of 
currently available antibiotics in respect of kill multidrug 
MRSA. Our findings showed that all the oxacillin resistant 
S. aureus were not mecA positive. Although presence of 
mecA gene in S. aureus  is traditionally considered as 
marker for MRSA, mecA negative oxacillin resistant S. 
aureus have been reported, recently [16, 17].  
The synergistic effects of ZnO-NPs to different 
antibiotics against some pathogens have been 
determined recently [18]. However, their synergistic 
effects against antibiotic resistant pathogens such as 
MRSA remained to be explored. In the present study, we 
have determined the synergistic effects of ZnO-NPs to 
different antibiotics against mecA positive MRSA isolates 
recovered from medical settings. The antibacterial 
activity of ZnO-NPs were tested using three different 
concentrations which were chosen to assure that the 
antibacterial effect produced was due to the combined 
effect of ZnO-NPs and antibiotics as suggested in 
previous report [19]. Antibiotics were carefully chosen 
because they represent the key classes of antibiotics 
(penicillins, cephalosporin, fluoroquinolones, and 
glycopeptides). However, our data showed that all 
antibiotics representing the key classes of antibiotics 
(penicillins, cephalosporin, fluoroquinolones, and 
glycopeptides) act differently in the presence of ZnO-
NPs. In Agreement with a previous study, antibacterial 
activity of ampicillin, cefotaxime and oxacillin in 
combination with ZnO-NPs against MRSA neither 
increased nor decreased [19]. Interestingly, the activity 
of levofloxacin and amoxicillin-clavulanic acid was 
increased in the presence of ZnO-NPs against the test 
MRSA strains. The increase in the diameter of the zone 
of inhibition of MRSA growth suggested that ZnO-NPs 
has positive synergistic effects on levofloxacin in terms 
of killing the levofloxacin resistant MRSA isolates. These 
findings are comparable to the results found previously 
[20], whereas the activity of vancomycin was reduced 
slightly against MRSA which is  similar to previous study 
in which the vancomycin zone diameter was reduced 
from 19mm to 18mm in the presence of ZnO-NPs [19]. 
Our data suggests that the ZnO-NPs provide synergism 
selectively presumably depending upon the different 
mode of action of antibiotics. 
Levofloxacin, an L-form isomer of ofloxacin, is a 
renowned member of fluoroquinolones which has broad 
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negative bacteria [21]. Like other fluoroquinolone, 
levofloxacin has ability to enter bacterial cells and to act 
on bacterial topoisomerase II (DNA gyrase) resulting the 
inhibition of super helical twists in bacterial DNA. Given 
that there are nitrogen atoms in quinolone ring in 
levofloxacin, the hydroxylated surface of ZnO-NPs can 
bring the possibility of ionic interactions between them 
and may cause stabilization of  levofloxacin and ZnO-
NPs system [22, 23]. In conclusion, ZnO-NPs have the 
potential of providing synergism to antibiotics which may 
open the doors for a future strategy of using 
combinational therapy against MRSA. 
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